Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
1. Xilio appoints Akintunde Bello to board, enhancing leadership expertise. 2. Bello brings 25 years of oncology experience from BMS and Pfizer. 3. Xilio focuses on tumor-activated immuno-oncology therapies for cancer treatment. 4. Company develops novel therapies to overcome existing treatment limitations. 5. Forward-looking statements hint at potential risks and milestones ahead.